Close

Analyst Ratings for BioXcel Therapeutics (BTAI) [Neutrals]

BTAI Rating Summary

BTAI Price Target Summary

* Over Last 12-Mos
  |   Expand Research on BTAI
Overall Rating: BUY   Rating Trend: Up   Avg. $ Target: $6.08 (+111.2%) * Over Last 12-Mos
Rating Score: 5 / 10   Percentile Rank: 53%
Date Firm Analyst Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
2/21/2024 UBS
» Updated 3/13/2024
Colin Bristow Downgrade Neutral
(Buy)
3.50
(4.00)
3.51
(2.88)
-17.95% Details
10/4/2023 Truist Securities Robyn Karnauskas Downgrade Hold
(Buy)
N/A
(N/A)
2.34
(2.88)
23.08% Details
Like BTAI Ratings? Also take a look at STX, BAX, IBRX, SMCI

BTAI Ratings News